Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy

Progestin-primed ovarian stimulation

“…No difference was found in embryo euploidy rates in any of the three, though the two largest studies detected similar pregnancy outcomes. Giles et al reported lower miscarriage rates in the PPOS group [32 ▪ ], an unusual finding that may have been a result of the sample size [1 ▪▪ ].…”

“…In a multicenter, retrospective cohort study of 1652 social fertility preservation cycles Giles et al found no differences in number of oocytes retrieved or number of mature oocytes vitrified when PPOS and GnRH antagonist protocols were compared [32 ▪ ].…”

“…Three recent retrospective cohort studies have compared PPOS and GnRH antagonist protocols in a combined total of 7000 cycles [32 ▪ ,34,35]. No difference was found in embryo euploidy rates in any of the three, though the two largest studies detected similar pregnancy outcomes.…”

“…PPOS protocols use oral medication, in contrast to the subcutaneous injections administered in other protocols, and when PPOS is applied in the luteal phase or for random start, it avoids menstrual bleeding during stimulation. These are some of the ways in which this protocol is more patient-friendly [10,32 ▪ ,33].…”

“…A further aspect to take into account, in addition to the advantages of oral administration, is that this type of protocol reduces the number of ultrasounds and analytical controls necessary to monitor follicular development, thus reducing costs indirectly [32 ▪ ]. These patient-friendly aspects of PPOS are likely to be especially appreciated by oncological patients and to reduce the stress associated with treatment in such a sensitive population [10].…”